← Leaderboards
Yi Tan
University Of Louisville
$5,480,724
Attributed
$5,480,724
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,480,724 · 3
By mechanism
R01$5,480,724 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Louisville
Same institution · by research overlap
- Aruni Bhatnagar Bhatnagar$35,834,843
- David E. Clouthier$11,870,732
- Gregg Rokosh$3,941,007
- Roberto Bolli$36,238,342
- Jordan T Noe$166,400
Others in their field
Other Emerging Leaders on “Pathologic”
- Ted Ross · University Of Georgia$68,763,143
- Dale Sandler · Social And Scientific Systems, Inc.$59,740,435
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Leonard Freedman · Leidos Biomedical Research, Inc.$41,527,040
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
Research focus
PathologicInsightCellsPreventCardiovascular DiseasesMediatingKnockout MiceFutureSiteClinical PracticeDiabetes MellitusChronicPathogenesisLipidsLife StyleNon-Insulin-Dependent Diabetes MellitusInjuryAgonistHeartCardiacGenetic TranscriptionInfarctionCxcr4 ReceptorsCxcr4 Gene
Grant awards (11)
Dual targeting chemokine receptors prevents chemotherapy-induced cardiotoxicity$681,996
R01 · FY2025 · HL · contact PI
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis$532,418
R01 · FY2025 · HL · contact PI
Dual targeting chemokine receptors prevents chemotherapy-induced cardiotoxicity$689,232
R01 · FY2024 · HL · contact PI
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis$531,739
R01 · FY2024 · HL · contact PI
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis$545,630
R01 · FY2023 · HL · contact PI
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis$553,582
R01 · FY2022 · HL · contact PI
A novel mechanism of stromal cell-derived factor 1 protection against diabetic cardiomyopathy$383,784
R01 · FY2021 · HL · contact PI
A novel mechanism of stromal cell-derived factor 1 protection against diabetic cardiomyopathy$383,805
R01 · FY2020 · HL · contact PI
A novel mechanism of stromal cell-derived factor 1 protection against diabetic cardiomyopathy$383,827
R01 · FY2019 · HL · contact PI
A novel mechanism of stromal cell-derived factor 1 protection against diabetic cardiomyopathy$391,747
R01 · FY2018 · HL · contact PI
A novel mechanism of stromal cell-derived factor 1 protection against diabetic cardiomyopathy$402,964
R01 · FY2017 · HL · contact PI